Barclays Forecasts Strong Price Appreciation for Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Key Points

• Barclays raised its price target on Teva to $40 (from $38) and kept an "overweight" rating, implying about an 11.6% upside$41.78.
• Despite analyst optimism, insiders have sold heavily — about 1,086,339 shares worth roughly $35.85 million in the past three months — while TEVA trades around $35.85 (market cap ~$41.2B, PE ~27).

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price target increased by research analysts at Barclays from $38.00 to $40.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's target price would indicate a potential upside of 11.57% from the stock's current price.

A number of other research firms have also commented on TEVA. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, April 9th. The Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, April 30th. Finally, Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a research report on Saturday. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $41.78.

Teva Pharmaceutical Industries Stock Down 0.0%

TEVA traded down $0.01 during midday trading on Wednesday, hitting $35.85. 2,367,962 shares of the company's stock traded hands, compared to its average volume of 8,200,592. The company has a market cap of $41.22 billion, a PE ratio of 26.97, a price-to-earnings-growth ratio of 3.42 and a beta of 0.86. The stock's fifty day simple moving average is $31.19 and its 200-day simple moving average is $29.57. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries has a one year low of $14.99 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $3.98 billion for the quarter. As a group, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.49 earnings per share for the current fiscal year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the sale, the insider owned 6,774 shares in the company, valued at $214,532.58. The trade was a 67.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the sale, the insider owned 80,760 shares in the company, valued at $2,825,792.40. This represents a 64.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,086,339 shares of company stock valued at $35,852,268. 0.54% of the stock is owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $25,000. Allworth Financial LP raised its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust raised its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock valued at $31,000 after buying an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after buying an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC raised its holdings in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after purchasing an additional 292 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.